Prostacyclin ( DrugBank: Prostacyclin )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	10

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05427162 (ClinicalTrials.gov)	June 21, 2022	16/6/2022	A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist	Open-Label, Randomized Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Mu ...	Pulmonary Arterial Hypertension	Drug: Prostacyclin Receptor Agonist	Actelion	NULL	Recruiting	18 Years	55 Years	All	86	Phase 1	United States
2	JPRN-UMIN000025176	2017/01/01	15/12/2016	Efficacy, tolerability, and safety of transition from beraprost to selexipag in patients with pulmon ...	Efficacy, tolerability, and safety of transition from beraprost to selexipag in patients with pulmon ...	Pulmonary arterial hypertension	Medicine transition from beraprost to selexipag In accordance with the Japanese package insert (http: ...	Hamamatsu University School of Medicine	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	33	Not selected	Japan
3	EUCTR2016-003495-53-NL (EUCTR)	29/11/2016	15/12/2016	Study on the effect of the drug selexipag in adult patients with elevated pressure in the pulmonary ...	Prostacyclinreceptor agonist Selexipag in patients with pulmonary arterial hypertension and congenit ...	Pulmonary arterial hypertension related to congenital heart disease.;Therapeutic area: Diseases [C] ...	Trade Name: Selexipag Product Name: Selexipag	Academic Medical Center - Cardiology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 3	Netherlands
4	NCT02436512 (ClinicalTrials.gov)	June 2015	13/4/2015	Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide	A Phase 3 Open-label Multi-Center, Two-Part Single-arm Study to Evaluate the Acute Vasodilation Resp ...	Pulmonary Arterial Hypertension	Drug: Inhaled Nitric Oxide	Geno LLC	NULL	Withdrawn	18 Years	70 Years	Both	0	Phase 3	United States
5	NCT02276872 (ClinicalTrials.gov)	December 18, 2014	21/10/2014	Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to ...	A Multicenter, Open-Label, 24-Week, Uncontrolled Study to Evaluate the Safety, Tolerability, and Pha ...	PAH	Drug: oral treprostinil	United Therapeutics	NULL	Completed	7 Years	17 Years	All	32	Phase 2	United States
6	NCT01266265 (ClinicalTrials.gov)	December 2010	22/12/2010	Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA A ...	A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial ...	Pulmonary Arterial Hypertension	Drug: inhaled prostacyclin;Drug: prostacyclin;Drug: subcutaneous and intravenous prostacyclin;Drug: ...	United Therapeutics	NULL	Completed	N/A	N/A	All	1333	N/A	United States
7	NCT01077297 (ClinicalTrials.gov)	August 2010	25/2/2010	Tezosentan in Pulmonary Arterial Hypertension	Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of ...	Pulmonary Arterial Hypertension	Drug: Tezosentan	Idorsia Pharmaceuticals Ltd.	NULL	Terminated	18 Years	N/A	All	3	Phase 2	United States;France;Switzerland
8	NCT01268553 (ClinicalTrials.gov)	August 2010	29/12/2010	Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication	Transition From Parenteral Prostanoids to Inhaled Treprostinil	Pulmonary Arterial Hypertension	Drug: Treprostinil	Los Angeles Biomedical Research Institute	United Therapeutics	Completed	18 Years	80 Years	All	6	Phase 4	United States
9	EUCTR2009-012450-20-FR (EUCTR)	15/10/2009	07/09/2009	Multicenter, open-label, non-comparative, proof-of-concept, phase 2a study to evaluate the effect of ...	Multicenter, open-label, non-comparative, proof-of-concept, phase 2a study to evaluate the effect of ...	Pulmonary arterial hypertension MedDRA version: 12.0;Level: LLT;Classification code 10064911;Term: P ...	Product Name: Tezosentan Product Code: ACT-050089 (Ro 61-0612) INN or Proposed INN: tezosentan Other de ...	Actelion Pharmaceuticals Ltd.	NULL	Not Recruiting			Female: yes Male: yes	13	Phase 2	France
10	NCT00159861 (ClinicalTrials.gov)	July 2003	8/9/2005	The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in P ...	A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to ...	Pulmonary Hypertension	Drug: Sildenafil citrate	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Pfizer	Completed	16 Years	N/A	All	267	Phase 3	United States;Belgium;Canada;Czechia;Denmark;France;Israel;Italy;Netherlands;Spain;United Kingdom;Cz ...

First Previous1Next Last